Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
  1. Home
  2. Search

Refine search

Refine search

Access:
Content type:
Publication date:
Apply
Subject: Show more
Journals Show more
Publishers: Show more
Societies Show more
Series: Show more
Collections: Show more

Actions for selected content:

Select all | Deselect all
  • View selected items
  • Export citations
  • Download PDF (zip)
  • Save to Kindle
  • Save to Dropbox
  • Save to Google Drive

Save Search

You can save your searches here and later view and run them again in "My saved searches".

Please provide a title, maximum of 40 characters.
Cancel
×

2 results

  • 12 - In utero hematopoietic cell transplantation
  • from Part 4 - Trophoblast, amniotic fluid, endometrium, and bone marrow
  • Edited by Carlos Simón, Antonio Pellicer, Renee Reijo Pera
  • Book: Stem Cells in Reproductive Medicine
  • Published online: 05 July 2013
  • Print publication: 04 July 2013, pp 133-139
  • View extract

    Summary

    Hematopoietic stem-cell disorders such as sickle cell disease, thalassemias, and immunodeficiencies may be the most amenable diseases to consider for in utero treatment. Despite the theoretical advantages of in utero hematopoietic cell transplantation (IUHCTx) and its success in animal models, its efficacy in humans has been limited, and current research efforts are focused on understanding and surmounting the barriers to engraftment in the fetus. The observation that selective depletion of host hematopoietic stem cells (HSCs) prior to bone-marrow (BM) transplant results in high rates of engraftment in adult animals suggests that vacating host stem cell niches may improve chimerism after IUHCTx. Two recent studies in mice have implicated the maternal immune system in rejecting the in utero transplanted cells, and have rekindled enthusiasm in this field. Achieving donor-specific tolerance after IUHCTx has the potential to treat many hematopoietic disorders.